These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37219716)

  • 1. A Milestone in the Treatment of Ataxias: Approval of Omaveloxolone for Friedreich Ataxia.
    Subramony SH; Lynch DL
    Cerebellum; 2024 Apr; 23(2):775-777. PubMed ID: 37219716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia.
    Pilotto F; Chellapandi DM; Puccio H
    Trends Mol Med; 2024 Feb; 30(2):117-125. PubMed ID: 38272714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omaveloxolone: potential new agent for Friedreich ataxia.
    Lynch DR; Johnson J
    Neurodegener Dis Manag; 2021 Apr; 11(2):91-98. PubMed ID: 33430645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia.
    Profeta V; McIntyre K; Wells M; Park C; Lynch DR
    Expert Opin Investig Drugs; 2023 Jan; 32(1):5-16. PubMed ID: 36708320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia.
    Lynch DR; Farmer J; Hauser L; Blair IA; Wang QQ; Mesaros C; Snyder N; Boesch S; Chin M; Delatycki MB; Giunti P; Goldsberry A; Hoyle C; McBride MG; Nachbauer W; O'Grady M; Perlman S; Subramony SH; Wilmot GR; Zesiewicz T; Meyer C
    Ann Clin Transl Neurol; 2019 Jan; 6(1):15-26. PubMed ID: 30656180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).
    Lynch DR; Chin MP; Delatycki MB; Subramony SH; Corti M; Hoyle JC; Boesch S; Nachbauer W; Mariotti C; Mathews KD; Giunti P; Wilmot G; Zesiewicz T; Perlman S; Goldsberry A; O'Grady M; Meyer CJ
    Ann Neurol; 2021 Feb; 89(2):212-225. PubMed ID: 33068037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerations.
    Lynch DR; Perlman S; Schadt K
    Expert Rev Neurother; 2024 Mar; 24(3):251-258. PubMed ID: 38269532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data.
    Lynch DR; Goldsberry A; Rummey C; Farmer J; Boesch S; Delatycki MB; Giunti P; Hoyle JC; Mariotti C; Mathews KD; Nachbauer W; Perlman S; Subramony SH; Wilmot G; Zesiewicz T; Weissfeld L; Meyer C
    Ann Clin Transl Neurol; 2024 Jan; 11(1):4-16. PubMed ID: 37691319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omaveloxolone: First Approval.
    Lee A
    Drugs; 2023 Jun; 83(8):725-729. PubMed ID: 37155124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and genetic analysis of 188 families with spinocerebellar degeneration. Friedreich's disease and P. Marie's hereditary ataxias].
    Ben Hamida M; Attia-Romdhane N; Triki CH; Oueslati S; Hentati F
    Rev Neurol (Paris); 1991; 147(12):798-808. PubMed ID: 1780608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension.
    Lynch DR; Chin MP; Boesch S; Delatycki MB; Giunti P; Goldsberry A; Hoyle JC; Mariotti C; Mathews KD; Nachbauer W; O'Grady M; Perlman S; Subramony SH; Wilmot G; Zesiewicz T; Meyer CJ
    Mov Disord; 2023 Feb; 38(2):313-320. PubMed ID: 36444905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates.
    Reisman SA; Gahir SS; Lee CI; Proksch JW; Sakamoto M; Ward KW
    Drug Des Devel Ther; 2019; 13():1259-1270. PubMed ID: 31118567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approval of omaveloxolone for Friedreich ataxia.
    Boesch S; Indelicato E
    Nat Rev Neurol; 2024 Jun; 20(6):313-314. PubMed ID: 38570703
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular genetics of hereditary ataxias.
    Banfi S; Zoghbi HY
    Baillieres Clin Neurol; 1994 Aug; 3(2):281-95. PubMed ID: 7952848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominant ataxias and Friedreich ataxia: an update.
    Albin RL
    Curr Opin Neurol; 2003 Aug; 16(4):507-14. PubMed ID: 12869811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omaveloxolone (Skyclarys
    Dayalan Naidu S; Dinkova-Kostova AT
    Trends Pharmacol Sci; 2023 Jun; 44(6):394-395. PubMed ID: 37142519
    [No Abstract]   [Full Text] [Related]  

  • 17. Progressive cerebellar atrophy: hereditary ataxias and disorders with spinocerebellar degeneration.
    Wolf NI; Koenig M
    Handb Clin Neurol; 2013; 113():1869-78. PubMed ID: 23622410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hereditary ataxias: Where are we now? Four decades of local research.
    Smith DC; Greenberg LJ; Bryer A
    S Afr Med J; 2016 May; 106(6 Suppl 1):S38-41. PubMed ID: 27245522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing phase II clinical trials in Friedreich ataxia.
    Rodden LN; Lynch DR
    Expert Opin Emerg Drugs; 2021 Dec; 26(4):415-423. PubMed ID: 34693848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New insights in the molecular genetics and pathophysiology of hereditary ataxias].
    Bürk K; Klockgether T; Dichgans J
    Nervenarzt; 1999 Jun; 70(6):491-5. PubMed ID: 10412692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.